Compare ARI & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | IVA |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 737.1M |
| IPO Year | 2009 | 2020 |
| Metric | ARI | IVA |
|---|---|---|
| Price | $6.42 | $3.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $8.00 | ★ $15.20 |
| AVG Volume (30 Days) | ★ 3.3M | 2.9M |
| Earning Date | 11-02-2026 | 09-28-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | ★ 183.51 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $271,589,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.11 | $2.82 |
| 52 Week High | $11.24 | $7.98 |
| Indicator | ARI | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 56.06 |
| Support Level | $6.11 | $3.23 |
| Resistance Level | $6.47 | $3.76 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 84.13 | 93.62 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.